4 Penny Stocks to Watch Right Now
What goes into putting together a good list of penny stocks? For starters, you want to find companies or stocks that you like. They might be high volume penny stocks are simply a handful of cheap stocks under 10 cents. While you may not find the next Apple Inc. (AAPL Stock Report) or Tesla (TSLA Stock Report), you could find some opportunities for short-term gains. I say short-term in the sense that most of these stocks under $5 experience short spurts of upward momentum for days to weeks and maybe, the occasional “months”.
Everybody has heard of penny stocks at some point if you have been investing in the market. Many investors have turned to these as a way to enter the market at a low cost. Some new traders will think that penny stocks are just a quick way to make a profit. While this situation could be true, it’s also possible to lose money just as fast as you can make it.
There are plenty of penny stocks that will reach new record highs every day, but does that mean you should invest in them? The simple fact is, all penny stocks aren’t good investments. Furthermore, all penny stocks aren’t good “trades,” they might take longer to work out than just a few days. For instance, if a penny stock is at a high price but its trading volume is low, it could be set to drop. That’s why it’s always important to do your research and not always take a stock by its face value, its stock price.
On the same token, look at other factors if you’re looking to invest in penny stocks. You should look for high volume, consistent trends, and recent developments from a company among other things. We’ve got a 60+ page eBook you can get for free by clicking here. With that being said, let’s take a look at a few penny stocks that have started establishing a stronger trend recently.
Top Penny Stocks To Watch Right Now: GT Biopharma Inc.
GT Biopharma Inc. (GTBP Stock Report) is one of the top biotech penny stocks we’ve discussed for a few weeks now. The initial jump came after the company gave a trial update on its Phase I/II trial of its lead candidate, GTB-3550. This is GT’s immunotherapy treatment, initially, for acute myeloid leukemia (AML). In late September the company reported that the first patient enrolled at Dose Level 3 in its GTB-3550 TriKE™ clinical trial, which showed positive findings. This included improvement in marrow cellularity, a decrease in AML blast levels, and improving platelet and red blood cell numbers.
Why it’s important to note interim data is he can give a gauge of progress or lack thereof. In this case, however, GT’s findings further support continued efforts in this trial. What’s more is that there’s a much bigger picture when it comes to GT’s treatment platform. It’s developed, TriKE™, a combination protein. It bridges an immune cell and a tumor cell to drive tumor cell killing power exponentially and has led to new first-in-human phase studies to treat leukemia along with other immune diseases.
The company recently expanded upon the TriKE™ platform. Last week the company announced that Cytovance® Biologics signed a deal with GT to manufacture TriKE™ using Cytovance’s proprietary Keystone® bacterial or mammalian expression systems. This week, not only has the company brought on more members to its Advisory board to expand TriKE™ for other cancers like prostate, but it also came out with another industry-related update today.
What To Watch With GTBP Stock
Thursday’s news gives the market a firm date and timely for what could be a point of focus. GT announced that its abstract on GTB-3550 TriKE™, has been selected by the Program Committee for presentation in an Oral Session at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on December 5th. What’s more is that the company said the abstract will also be published online in November supplemental issue of the journal Blood.
The first publication will be in the online ASH meeting program on November 5, 2020. In light of these developments, we’ve seen GTBP stock climb from around $0.15 in late-September to highs this week of $0.25. What’s more, is that Thursday’s afternoon session saw a late-afternoon surge into the close. GTBP stock closed at its high of the day.
Top Penny Stocks To Watch Right Now: Nano Dimension Ltd.
Unlike GT Biopharma, Nano Dimension Ltd. (NNDM Stock Report) is a tech company, that has been performing well throughout 2020. The company creates technology called Additively Manufactured Electronics. This technology is electromechanical and helps with different types of products such as autonomous drones, cars, cell phones, and much more. Nano Dimension actively uses 3D printing technology to create electronics as well. Now let’s take a dive into the recent news for this tech company
- What Are The Best Penny Stocks To Buy Right Now? 3 Up Big This Week
- What Are The Best Penny Stocks To Buy Today? 3 For Your List
On October 5th, Nano Dimension announced the closure of a registered direct offering of 7,356,521 of the company’s American Depositary Shares at $2.30 per ADS. The gross proceeds that resulted from this offering is $16.9 million. In addition to this, the company also announced its second-quarter financial results back in August. Nano stated that its revenue was $288,000 for the second quarter of 2020. This is much lower than the $702,000 in revenue it produced back in the first quarter of this year. The decrease was due to delays of identified transactions of DragonFly systems, attributed to the coronavirus pandemic.
Yael Sandler, the CEO of the company stated, “As projected by our President & CEO in our last investors conference call in mid-May, the global effects of the Covid-19 pandemic have caused a material decrease to our revenues, since companies and organizations around the world are not releasing budgets for purchases of capital equipment.”
What To Watch With NNDM Stock?
On October 15th, NNDM stock continued its climb, with a volume of over 32 million shares. This is far above the average volume of around 5.6 million. What should be considered, however, is the extent of this latest move. NNDM stock has climbed by more than 100% over the last few weeks and Thursday was, by far, one of its biggest 1-day moves.
Even since the start of the week when we touched upon the penny stock, it’s climbed over 60%. It has become a popular stock among traders but as we know, nothing goes up forever. So if NNDM is on your list of penny stocks to watch, be well-aware of how it has traded in the past, leading up to Thursday.
Top Penny Stocks To Watch Right Now: Trevena Inc.
Next up on this list of penny stocks is Trevena Inc. (TRVN Stock Report), a biopharmaceutical company that develops and commercializes medicines for treating central nervous system disorders. It’s also another one of the penny stocks we’ve discussed for quite some time now.
Coincidentally, it was also on our list of top biotech penny stocks to watch in October. Its products include Oliceridine injection, which has completed Phase III trials to manage moderate to severe acute pain. It has many other products as well. Since June 2nd we’ve followed this company and a lot has happened during that time. The company began collaborating with Imperial College London.
The goal was to evaluate the treatment potential of TRV027 for acute lung injury in COVID patients. What’s more, is that the most recent focus has been on the company’s non-COVID pipeline. Its OLINVYK treatment was also featured in a few publications. OLINVYK is used to treat moderate to severe acute pain in adults and was compared to the safety of IV morphine.
What To Watch With TRVN Stock?
In recent times, Trevena is working with Imperial College London to evaluate trv027 in COVID-19 patients. At the Virtual American Society of Anesthesiologists 2020 Annual Meeting, Trevena announced three OLINVYK presentations. The company announced that its phase 3 programs are going well.
The Senior VP and Chief Medical Officer of the company said, “Throughout its clinical development, OLINVYK has demonstrated a consistently favorable side effect profile. I am pleased that we are still gaining valuable clinical insights into its differentiated profile as we continue to examine the robust Phase 3 data, which is clearly of great interest to clinicians looking for alternative treatment options for the treatment of acute pain.”
[Read More] 4 Penny Stocks To Watch Under $4 In October 2020
OLINVYK was approved by the FDA back in August 2020. This success has resulted in large increases in share price for TRVN stock as well. On October 15th, TRVN stock made a nice rebound after several days of downward pressure. Needless to say, TRVN stock price is up 248.8% year-to-date.
Top Penny Stocks To Watch Right Now: Antero Resources Corporation
Last but not least on this list of penny stocks is Antero Resources Corporation (AR Stock Report). Antero is an independent oil and natural gas company. Its primary focus is the acquisition, exploration, development, and production of natural gas, natural gas liquids, and oil properties. Its properties are all located in the United States. It actively has more than 500,000 net acres of land. It is estimated that the company had 18.9 trillion proven reserves of natural gas equivalent. But why is AR stock’s volume up on the day of October 15th?
Well, it was just announced on October 14th that Antero Resources Corporation will be presenting its third quarter 2020 earnings on October 28th. This will take place via earnings release and conference call. In its last quarterly earnings, its revenue declines by 52.27% year over year. It seems like analysts and investors are expecting better results for Antero Resources third quarter results. Only time will tell, and we will see what truly has happened to the company’s financials when the October 28th report is released.
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), GT Biopharma is required to pay $200,000 per month for 4 months of services, $400,000 of which has already been paid for 2 months of services (first and last month) for a period from September 22, 2020 to January 22, 2021. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP).